Myoferlin Alleviates Pressure Overload-induced Cardiac Hypertrophy and Dysfunction by Inhibiting NLRP3-mediated Pyroptosis

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2024 Nov 18

PMID 39553724

Authors

Yang Zhou

Yanxu Liu

Hao Luo

Cong Wen

Yangyang Cui

Linqing Du

Ofe Eugene Kwaku

Lan Li

Lijuan Xiong

Jiankang Zheng

Xuefeng Ding

Xiufeng Shen

Peng Zhou

Houxiang Hu

Rongchuan Yue

Affiliations

Soon will be listed here.

Abstract

Myoferlin (MYOF) is a muscle-derived secretory protein. Recent studies have found that MYOF protects against cell damage. However, the role of MYOF in cardiac hypertrophy remains unclear. Increasing evidence suggests that NLRP3 (NOD-like receptor protein 3) and the pyroptosis cascade play critical roles in the development of cardiac hypertrophy and inflammation. To investigate the role of MYOF in cardiac hypertrophy, we conducted a transverse aortic constriction (TAC) experiment in a mouse model. We found that MYOF can improve cardiac hypertrophy and cardiac function. Furthermore, our study confirmed a connection between cardiac hypertrophy and myocardial pyroptosis. Cardiac hypertrophy significantly increased the proportion of apoptotic cells and upregulated apoptosis-associated speck-like protein containing a CARD (ASC), caspase-1, and gasdermin D (GSDMD). This suggests that pharmacological or genetic inhibition of NLRP3 can effectively reduce cardiac hypertrophy. An abnormal increase in NLRP3 can reverse the cardioprotective effects of MYOF. Our findings indicate that MYOF is a potential therapeutic agent for cardiac hypertrophy.

References

Bernatchez P, Sharma A, Kodaman P, Sessa W . Myoferlin is critical for endocytosis in endothelial cells. Am J Physiol Cell Physiol. 2009; 297(3):C484-92. PMC: 2740391. DOI: 10.1152/ajpcell.00498.2008. View

Luo T, Yue R, Hu H, Zhou Z, Yiu K, Zhang S . PD150606 protects against ischemia/reperfusion injury by preventing μ-calpain-induced mitochondrial apoptosis. Arch Biochem Biophys. 2015; 586:1-9. DOI: 10.1016/j.abb.2015.06.005. View

Fink S, Cookson B . Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005; 73(4):1907-16. PMC: 1087413. DOI: 10.1128/IAI.73.4.1907-1916.2005. View

Doherty K, Demonbreun A, Wallace G, Cave A, Posey A, Heretis K . The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J Biol Chem. 2008; 283(29):20252-60. PMC: 2459265. DOI: 10.1074/jbc.M802306200. View

Han S, Cui C, He H, Shen X, Chen Y, Wang Y . Myoferlin Regulates Wnt/β-Catenin Signaling-Mediated Skeletal Muscle Development by Stabilizing Dishevelled-2 Against Autophagy. Int J Mol Sci. 2019; 20(20). PMC: 6829482. DOI: 10.3390/ijms20205130. View

Habimana O, Salami O, Peng J, Yi G . Therapeutic implications of targeting pyroptosis in Cardiac-related etiology of heart failure. Biochem Pharmacol. 2022; 204:115235. DOI: 10.1016/j.bcp.2022.115235. View

Ren B, Feng J, Yang N, Guo Y, Chen C, Qin Q . Ginsenoside Rg3 attenuates angiotensin II-induced myocardial hypertrophy through repressing NLRP3 inflammasome and oxidative stress via modulating SIRT1/NF-κB pathway. Int Immunopharmacol. 2021; 98:107841. DOI: 10.1016/j.intimp.2021.107841. View

Luo Y, Tang X, An X, Xie X, Chen X, Zhao X . SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. Eur Heart J. 2016; 38(18):1389-1398. DOI: 10.1093/eurheartj/ehw138. View

Bergsbaken T, Fink S, Cookson B . Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009; 7(2):99-109. PMC: 2910423. DOI: 10.1038/nrmicro2070. View

10.

Demonbreun A, Quattrocelli M, Barefield D, Allen M, Swanson K, McNally E . An actin-dependent annexin complex mediates plasma membrane repair in muscle. J Cell Biol. 2016; 213(6):705-18. PMC: 4915191. DOI: 10.1083/jcb.201512022. View

11.

Nakamura M, Sadoshima J . Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018; 15(7):387-407. DOI: 10.1038/s41569-018-0007-y. View

12.

Davis D, Delmonte A, Ly C, MCNALLY E . Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum Mol Genet. 1999; 9(2):217-26. DOI: 10.1093/hmg/9.2.217. View

13.

Doherty K, Cave A, Davis D, Delmonte A, Posey A, Earley J . Normal myoblast fusion requires myoferlin. Development. 2005; 132(24):5565-75. PMC: 4066872. DOI: 10.1242/dev.02155. View

14.

Posey Jr A, Demonbreun A, McNally E . Ferlin proteins in myoblast fusion and muscle growth. Curr Top Dev Biol. 2011; 96:203-30. PMC: 4464798. DOI: 10.1016/B978-0-12-385940-2.00008-5. View

15.

Wu Q, Xiao Y, Yuan Y, Ma Z, Liao H, Liu C . Mechanisms contributing to cardiac remodelling. Clin Sci (Lond). 2017; 131(18):2319-2345. DOI: 10.1042/CS20171167. View

16.

Kovarova M, Hesker P, Jania L, Nguyen M, Snouwaert J, Xiang Z . NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice. J Immunol. 2012; 189(4):2006-16. PMC: 3635067. DOI: 10.4049/jimmunol.1201065. View

17.

Zhou W, Chen C, Chen Z, Liu L, Jiang J, Wu Z . NLRP3: A Novel Mediator in Cardiovascular Disease. J Immunol Res. 2018; 2018:5702103. PMC: 5911339. DOI: 10.1155/2018/5702103. View

18.

Li R, Lu K, Wang Y, Chen M, Zhang F, Shen H . Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression. Biochem Biophys Res Commun. 2017; 485(1):69-75. DOI: 10.1016/j.bbrc.2017.02.021. View

19.

Oldfield C, Duhamel T, Dhalla N . Mechanisms for the transition from physiological to pathological cardiac hypertrophy. Can J Physiol Pharmacol. 2019; 98(2):74-84. DOI: 10.1139/cjpp-2019-0566. View

20.

Ward R, Li W, Abdul Y, Jackson L, Dong G, Jamil S . NLRP3 inflammasome inhibition with MCC950 improves diabetes-mediated cognitive impairment and vasoneuronal remodeling after ischemia. Pharmacol Res. 2019; 142:237-250. PMC: 6486792. DOI: 10.1016/j.phrs.2019.01.035. View